BradleyJM, MoranFM, ElbornJS. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med, 2006; 100(2):191–201.
2.
FlumePA, RobinsonKA, O'SullivanBP, FinderJD, VenderRL, Willey-CourandDB, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care, 2009; 54(4):522–537.
3.
SchechterMS. Airway clearance applications in infants and children. Respir Care, 2007; 52(10):1382–1391.
4.
RubinBK. Designing clinical trials to evaluate mucus clearance therapy. Respir Care, 2007; 52(10):1348–1361.
5.
SchechterMS. Evaluating the evidence for airway-clearance therapy in cystic fibrosis. Respir Care, 2009; 54(4):458–460.
6.
MyersLB, HornSA. Adherence to chest physiotherapy in adults with cystic fibrosis. J Health Psychol, 2006; 11(6):915–926.
7.
OermannCM, SwankPR, SockriderMM. Validation of an instrument measuring patient satisfaction with chest physiotherapy techniques in cystic fibrosis. Chest, 2000; 118(1):92–97.
8.
HomnickDN. Making airway clearance successful. Paediatr Respir Rev, 2007; 8(1):40–45.
9.
MillaCE, HansenLG, WarwickWJ. Different frequencies should be prescribed for different high frequency chest compression machines. Biomed Instrum Technol, 2006; 40(4):319–324.
10.
KempainenRR, WilliamsCB, HazelwoodA, RubinBK, MillaCE. Comparison of high-frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis. Chest, 2007; 132(4):1227–1232.
11.
LesterMK, FlumePA. Airway-clearance therapy guidelines and implementation. Respir Care, 2009; 54(6):733–753.
12.
KempainenRR, MillaC, DunitzJ, SavikK, HazelwoodAnn, WilliamsC, et al. Comparison of settings used for high-frequency chest-wall compression in cystic fibrosis. Respir Care, 2010; 55(6):695–701.
13.
IngersollKS, CohenJ. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med, 2008; 31(3):213–224.
14.
Mayer-HamblettN, RamseyBW, KronmalRA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc, 2007; 4(4):370–377.
15.
QuittnerAL. Measurement of quality of life in cystic fibrosis. Curr Opin Pulm Med, 1998; 4(6):326–331.
